ENTA FY 2016 Earnings Report — Enanta Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

Enanta Pharmaceuticals, Inc.ENTA

FY 2016 Earnings

Reported January 6, 2017

Quarter Comparison

Revenue

Operating Income

Gross Margin

Net Margin

EPS (Diluted)

Free Cash Flow

Metric	FY 2016	Prior Q	FY 2015	QoQ Change	YoY Change
Revenue	$88M	—	$161M	—	-45.1%
Op. Income	$31M	—	$124M	—	-75.2%
Gross Margin	100.0%	—	100.0%	—	0.0pp
Net Margin	24.5%	—	49.1%	—	-24.6pp
EPS (Diluted)	$1.13	—	$4.09	—	-72.4%
Free Cash Flow	$31M	—	$74M	—	-58.2%

Revenue Flow

Item	Amount
REVENUE	$88M
Cost of Revenue	$0
GROSS PROFIT	$88M
R&D Expenses	$40M
Selling & Marketing	$0
General & Administrative	$17M
SG&A Expenses	$17M
Other Expenses	$0
Operating Expenses	$57M
Cost & Expenses	$57M
OPERATING INCOME	$31M
Interest Income	$2M
Interest Expense	$45.0K
Other Income/Expenses	$2M
INCOME BEFORE TAX	$33M
Income Tax Expense	$11M
Net Income from Continuing Ops	$22M
Net Income from Discontinued Ops	$0
Other Adjustments	$0
NET INCOME	$22M
Net Income Deductions	$0
BOTTOM LINE NET INCOME	$22M
D&A	$2M
EBIT	$31M
EBITDA	$33M
EPS	$1
EPS Diluted	$1

Income Statement

Item	Amount
REVENUE	$88M
Cost of Revenue	$0
GROSS PROFIT	$88M
R&D Expenses	$40M
Selling & Marketing	$0
General & Administrative	$17M
SG&A Expenses	$17M
Other Expenses	$0
Operating Expenses	$57M
Cost & Expenses	$57M
OPERATING INCOME	$31M
Interest Income	$2M
Interest Expense	$45.0K
Other Income/Expenses	$2M
INCOME BEFORE TAX	$33M
Income Tax Expense	$11M
Net Income from Continuing Ops	$22M
Net Income from Discontinued Ops	$0
Other Adjustments	$0
NET INCOME	$22M
Net Income Deductions	$0
BOTTOM LINE NET INCOME	$22M
D&A	$2M
EBIT	$31M
EBITDA	$33M
EPS	$1
EPS Diluted	$1

Cash Flow Statement

Item	Amount
Net Income	$22M
Depreciation & Amortization	$2M
Stock-Based Compensation	$9M
Deferred Income Tax	-$2M
Other Non-Cash Items	-$749.0K
Change in Working Capital	$6M
OPERATING CASH FLOW	$36M
Capital Expenditure	-$5M
Acquisitions (Net)	$0
Purchases of Investments	-$192M
Sales/Maturities of Investments	$154M
Other Investing Activities	-$39M
NET CASH FROM INVESTING	-$44M
Net Debt Issuance	-$68.0K
Common Stock Repurchased	$0
Common Dividends Paid	$0
Other Financing Activities	$3M
NET CASH FROM FINANCING	$3M
FREE CASH FLOW	$31M
Net Change in Cash	-$5M

Balance Sheet

Item	Amount
Cash & Equivalents	$17M
Short-Term Investments	$194M
Net Receivables	$13M
Inventory	$0
Other Current Assets	$9M
TOTAL CURRENT ASSETS	$232M
PP&E (Net)	$8M
Goodwill	$0
Intangible Assets	$0
Long-Term Investments	$32M
Tax Assets	$8M
Other Non-Current Assets	$608.0K
TOTAL NON-CURRENT ASSETS	$49M
TOTAL ASSETS	$281M
Account Payables	$3M
Short-Term Debt	$0
Deferred Revenue	$0
Other Current Liabilities	$0
TOTAL CURRENT LIABILITIES	$8M
Long-Term Debt	$0
Deferred Revenue NC	$207.0K
Deferred Tax Liabilities	$745.0K
Other Non-Current Liabilities	$3M
TOTAL NON-CURRENT LIABILITIES	$3M
TOTAL LIABILITIES	$11M
Common Stock	$190.0K
Additional Paid-In Capital	$242M
Retained Earnings	$28M
Treasury Stock	$0
Accum. Other Comp. Income	$19.0K
Other Equity	$0
TOTAL STOCKHOLDERS' EQUITY	$270M
Minority Interest	$0
TOTAL EQUITY	$270M
TOTAL LIABILITIES & EQUITY	$281M
Total Debt	$531.0K
Net Debt	-$16M